Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG (TiCAB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01755520|
Recruitment Status : Terminated (DSMB Interim Analyses)
First Posted : December 24, 2012
Last Update Posted : August 2, 2018
The primary objective of this study ist to test the hypothesis that ticagrelor is superior to Aspirin (ASA) fort he prevention of major cardio- and cerebrovascular events (MACCE) in patients undergoing artery bypass operation.
The primary efficiacy MACCE-endpoint is the composite of cardiovascular death, myocardial infarction, recurent revascularisation, and stroke at twelve month after coronary artery bypass operation.
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease Stable Angina Acute Coronary Syndrome||Drug: Ticagrelor Drug: Aspirin Drug: Placebo - Ticagrelor Drug: Placebo - Aspirin||Phase 3|
For stable patients who underwent coronary bypass operation, Aspirin alone currently represents the gold standard of antiplatelet treatment.
The CABG substudy of the PLATO-trial (http://www.nejm.org/doi/full/10.1056/NEJMoa0904327) comprising more than 1200 patients has convincingly shown a high significant reduction of cardiovascular and all-cause mortality for patients recieving Aspirin and Ticagrelor as compared to those subjects randomized to Aspirin plus Clopidogrel. Moreover the results of the PLATO CABG substudy showed that benefits of Ticagrelor increase with decreasing Aspirin doses. Therefore Ticagrelor monotherapy (2x 90mg/day) appears to offer the best balance of safety with anticipated improved efficacy over Aspirin (1x 100mg/day) alone, but until now there are no further data available to support this hypothesis.
Hence this study (TiCAB) is assigned as a pivotal efficacy and safety study of Ticagrelor in patients undergoing coronary artery bypass operation and to test the hypothesis that ticagrelor is superior to Aspirin for the prevention of major cardio- and cerebrovascular events (MACCE) in this patient population.
The TiCAB trial is designed as a randomized, double-blind, double-dummy, parallel group, phase III, multicenter study, comparing the efficacy and safety of Ticagrelor 90mg administered twice daily with Aspirin 100mg once daily, for the prevention of MACCE within the first year after CABG operation.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1893 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared With Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB- Ticagrelor in CABG|
|Study Start Date :||April 24, 2013|
|Actual Primary Completion Date :||May 19, 2018|
|Actual Study Completion Date :||May 19, 2018|
Intervention: Drug: Ticagrelor verum + Aspirin placebo
90mg twice daily dose
Other Name: Brilique
Drug: Placebo - Aspirin
Other Name: Placebo
Active Comparator: Aspirin
Intervention: Drug: Aspirin verum + Ticagrelor placebo
Aspirin 100mg once daily
Other Name: ASS
Drug: Placebo - Ticagrelor
Other Name: Placebo
- MACCE [ Time Frame: at 12 months after coronary artery bypass surgery ]Composite of cardiovascular death, myocardial infarction, target vessel revascularization, and stroke
- Cardiovascular death [ Time Frame: at 12 months after coronary artery bypass surgery ]
- Major bleeding events [ Time Frame: within 12 months after coronary arerty bypass surgery ]Incidence of major bleeding events
- All cause death [ Time Frame: at 12 months after coronary artery bypass surgery ]All cause death
- Myocardial Infarction [ Time Frame: at 12 months after coronary artery bypass surgery ]
- Target Lesion Revascularization [ Time Frame: at 12 months after coronary artery bypass surgery ]
- Stroke [ Time Frame: at 12 months after coronary artery bypass surgery ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01755520
|Study Chair:||Heribert Schunkert, MD||Deutsches Herzzentrum Munich Germany|